Duration of Rebamipide Therapy
Rebamipide can be taken for 3 months for radiation-induced oral mucositis, 12 weeks for NSAID-induced gastropathy prevention, or 8 weeks for treatment of aspirin-induced enteropathy, depending on the clinical indication.
Indication-Specific Duration Guidelines
Radiation-Induced Oral Mucositis
For patients receiving radiochemotherapy for head and neck cancer, rebamipide oral rinse (4% concentration, 5 mL for 30 seconds, six times daily) should be started three days before treatment and continued for three months 1. This extended duration covers the acute treatment period and allows for adequate mucosal healing during the recovery phase.
NSAID-Induced Gastropathy Prevention
When used as prophylaxis against NSAID-induced gastric ulcers, rebamipide 100 mg three times daily can be continued for 12 weeks 2. This duration was validated in a randomized controlled trial comparing rebamipide to misoprostol, demonstrating comparable efficacy in preventing gastric ulcers (20.3% vs 21.9% occurrence rate) with superior tolerability and significantly lower gastrointestinal symptom scores.
Low-Dose Aspirin-Induced Enteropathy
For treatment of established moderate-to-severe small intestinal damage from aspirin, a high-dose regimen of rebamipide 300 mg three times daily for 8 weeks is effective 3. This triple-dose regimen significantly reduced mucosal breaks and improved Lewis scores in patients with more than 3 erosions or ulcers on capsule endoscopy.
Post-Endoscopic Submucosal Dissection
Following ESD procedures, rebamipide 100 mg three times daily for 8 weeks accelerates ulcer healing 4. The combination with proton pump inhibitors showed significantly higher ulcer reduction rates at 4 weeks compared to PPI monotherapy.
Important Clinical Considerations
Safety profile supports extended use: Rebamipide demonstrates excellent tolerability across all studied durations, with only mild adverse effects (primarily dysgeusia and nasopharyngitis) and high adherence rates (96.8%) 5. No serious adverse events were reported in trials lasting up to 12 weeks 2.
Treatment can be extended beyond initial periods when clinically indicated, particularly for chronic conditions requiring ongoing mucosal protection. The 12-week duration studied for NSAID gastropathy prevention represents the longest validated continuous use period in controlled trials.
Common pitfall: Discontinuing therapy too early in radiation-induced mucositis. The 3-month duration is critical because mucosal damage continues to evolve after radiation completion, and premature cessation may result in inadequate healing.